Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
HC Wainwright & Co. Reiterates Neutral on Nektar Therapeutics, Lowers Price Target to $26
11:09am, Tuesday, 12'th May 2020H.C. Wainwright Sticks to Their Hold Rating for Nektar Therapeutics
10:27am, Tuesday, 12'th May 2020
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, setting a price target of $26, which is approximately 25.18% above the present sh
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.45%
12:00am, Monday, 11'th May 2020
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.45%
SVB Leerink Maintains Market Perform on Nektar Therapeutics, Raises Price Target to $18
03:19pm, Friday, 08'th May 2020Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates
02:29pm, Friday, 08'th May 2020
Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.
Nektar Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.
02:21pm, Friday, 08'th May 2020Edited Transcript of NKTR earnings conference call or presentation 7-May-20 9:00pm GMT
08:12am, Friday, 08'th May 2020
Q1 2020 Nektar Therapeutics Earnings Call
No Surprises in Nektar's Q1; COVID-19 Likely Just a Small Bump in Road for Bempeg Trials
07:57am, Friday, 08'th May 2020Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2020 Results - Earnings Call Transcript
07:31am, Friday, 08'th May 2020
Nektar Therapeutics (NASDAQ:NKTR) Q1 2020 Earnings Conference Call May 7, 2020 17:00 ET Company Participants Jennifer Ruddock - SVP, Strategy & Corporate Af
Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript
07:31am, Friday, 08'th May 2020
NKTR earnings call for the period ending March 31, 2020.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Thursday, 07'th May 2020
Nektar (NKTR) delivered earnings and revenue surprises of 34.57% and 12.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics Q1 EPS $(0.530) Beats $(0.710) Estimate, Sales $50.573M Beat $47.640M Estimate
09:13pm, Thursday, 07'th May 2020Nektar Therapeutics Reports First Quarter 2020 Financial Results
08:15pm, Thursday, 07'th May 2020
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020.
Pear Therapeutics to Present at the Bank of America Merrill Lynch 2020 Virtual Healthcare Conference
12:00am, Thursday, 07'th May 2020
Pear Therapeutics to Present at the Bank of America Merrill Lynch 2020 Virtual Healthcare Conference
